Manufacturers OEM

IDL Biotech AB

P.O. Box 111 51 , 161 11 Bromma
Karlsbodavägen 39 5tr , 16867 Bromma
Sweden

Telephone +46 8 7996750
Fax +46 8 7999320
idlbiotech@idl.se

Trade fair hall

  • Hall 1 / A34
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 1): stand A34

Fairground map

MEDICA 2016 fairground map: Hall 1

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.01  Diagnostic agents / kits for tumour marker determination

Diagnostic agents / kits for tumour marker determination

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.01  Bacteriology - Infectious immunology

Bacteriology - Infectious immunology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.08  Rapid tests - Infectious immunology

Our products

Product category: Tumor markers, Diagnostic agents / kits for tumour marker determination, Bacteriology - Infectious immunology, Rapid tests - Infectious immunology

MonoTotal For high sensitivity in NSCLC

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality worldwide. Patients may suffer from one of two cancer types: Non-Small Cell Lung Cancer (NSCLC), or the less common, Small-Cell Lung Cancer (SCLC).

Cancer biomarkers are effective for prognostic evaluation and monitoring of disease.MonoTotal® is a sensitive and efficient tool for the management of patients with Non-Small Cell Lung Cancer (NSCLC).

With MonoTotal®, physicians receive an early indication of disease status, measured in terms of tumor cell activity rather than more conventional tumor burden measurements.MonoTotal® provides the physician with a reliable monitoring aid for disease progression and treatment in lung cancer patients.

About Lung Cancer
Lung cancer kills more people than colon, breast, and prostate cancer combined (WHO statistics). An estimated 80-85 percent of lung cancer patients suffer from Non-Small Cell Lung Cancer (NSCLC). With approximately 15-20 percent of lung cancer patients diagnosed when the disease is still restricted to the lungs, early detection is critical to increasing the patient’s chances of survival. Surgical resection is one effective treatment for early stage NSCLC; however, the majority of patients suffer from an advanced and inoperable stage of the disease.

More Less

Product category: Tumor markers, Diagnostic agents / kits for tumour marker determination, Bacteriology - Infectious immunology, Rapid tests - Infectious immunology

TPS

TPS® is a tumor activity marker assay used to support prognosis, treatment monitoring, and patient follow-up for various epithelial cancers, including breast, colorectal, ovarian, and prostate cancer.

TPS® measures soluble fragments of cytokeratin 18, which is over-expressed in epithelial cells and particularly in many types of cancer. This information is crucial for early detection of cancer recurrence and the quick assessment of treatment efficacy.

More Less

Product category: Tumor markers, Diagnostic agents / kits for tumour marker determination, Bacteriology - Infectious immunology, Rapid tests - Infectious immunology

UBC

Bladder cancer is a common cancer in men and women worldwide. More than 70 percent of cases are non-muscle invasive bladder cancers, but many patients progress to muscle invasive bladder cancer or metastatic disease. To improve the prognosis of bladder cancer, employing effective methods for early detection and regular follow-up is vital for the patient.

Non-invasive bladder cancer tests have many potential applications, such as helping to diagnose recurrence, reducing the need for invasive testing, and detecting whether patients fall into a high-risk category. UBC® immunoassays are one type of non-invasive test.

About Bladder Cancer
Bladder cancer is three to four times more common in men than in women. Currently, more than 70 percent of cases are non-muscle invasive bladder cancers, but the recurrence rate is high. Therefore, many patients progress to muscle invasive bladder cancer or metastatic disease.

Cystoscopy and urine cytology are the most common methods for detection and assessment of recurrence of bladder cancer. Cystoscopy causes patients pain and discomfort, and, in cases with small tumors or carcinoma in situ, a diagnosis is not readily made. Urine cytology, a non-invasive urine test, is the standard method of detection for bladder cancer and is a recommended supplement to cystoscopy. Cytology has the advantage of high specificity, but shows low sensitivity for well-differentiated or low-grade tumors.

More Less

Product category: Tumor markers, Diagnostic agents / kits for tumour marker determination, Bacteriology - Infectious immunology, Rapid tests - Infectious immunology

TUBEX TF

TUBEX® TF Overview
 
TUBEX® TF enables diagnosis of acute phase disease by detection of infection-specificSalmonella typhi IgM anti-O9 antibodies in serum. TUBEX® TF is based on Inhibition Magnetic Binding Immunoassay, IMBI® technology — a semiquantitative assay technology utilizing the advantages of the traditional Widal technique, such as simplicity and visual interpretation of fluid. IMBI® technology exhibits specificity normally accorded to ELISAs through the use of purified antigens for detection.

How Our IMBI® Technology Boosts Typhoid Detection

More Less

About us

Company details

IDL Biotech AB offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. Our product portfolio consist of TUBEX®, TPS®, UBC®, UBC® Rapid , MonoTotal®and TPAcyk™.

More Less

Company data

Number of employees

1-19

Area of business

Diagnostics